Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ABP 072

Next Previous
Drug Profile

ABP 072

Alternative Names: ABP-072

Latest Information Update: 28 May 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Atom Bioscience
  • Class Antigouts; Azoles
  • Mechanism of Action Xanthine oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Gout

Most Recent Events

  • 28 May 2023 No recent reports of development identified for research development in Gout in China
  • 30 May 2019 Atom Bioscience has patent protection for xanthine oxidase inhibitor compounds in China, Japan, Europe, USA and other areas in the World before May 2019 (Atom Bioscience website, May 2019)
  • 01 Apr 2019 Early research in Gout in China before April 2019 (Atom Bioscience pipeline, April 2019)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top